One such PD-1-VEGFA-trap, AK112 (a humanized IgG1 bispecific anti-PD-1/VEGFA antibody), is currently being tested in multiple phase 2 clinical trials involving NSCLC, TNBC, and advanced gynecological tumors (NCT04736823, NCT05227664, NCT04870177). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.